Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tenet Healthcare Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Tenet Healthcare Corporation trades at $204.25 (market cap $17.59B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.3× Tenet Healthcare Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | THC | |
|---|---|---|
Market Cap | $39.89B | $17.59B |
Sector | Health | Health |
52-Week High | $491.22 | $244.80 |
52-Week Low | $278.09 | $148.38 |
Enterprise Value | $38.15B | $27.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Tenet Healthcare (THC) trades at $204.25, down 1.22% amid broader market weakness. The stock maintains strong fundamentals with a P/E of 10.62 and robust profitability metrics including 37.87% ROE. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show bullish momentum despite overbought RSI readings, with support at $204 and resistance at $209.
The outlook remains positive with 81% analyst buy ratings and a $233.63 consensus price target representing 14% upside. Key risks include healthcare regulatory pressures and execution challenges in outpatient expansion. Earnings growth from the Ambulatory Care segment and defensive positioning during geopolitical tensions provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
